Determination of Prevalence and Features of HRRm mCRPC (ADAM)

A Multi-center, Non-interventional, Prospective Cohort Study for Determination of Prevalence and Features of HRRm mCRPC (ADAM)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04712890

Acronym

ADAM

Enrollment

331

Registered

2021-01-15

Start date

2020-10-23

Completion date

2022-09-30

Last updated

2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HRRm mCRPC

Keywords

HRRm mCRPC

Brief summary

Study design: This study is local, multi-center, prospective, cohort study to collect real world data related mCRPC patients, prevalence of HRRm and to assess possible influence of HRRm on treatment outcomes. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice. Data Source(s): For testing archival samples (formalin fixed and paraffin embedded \[FFPE\]) from primary tumor will be used . 15 HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D and RAD54L) will be analyzed using NGS in dedicated central laboratory facilities. Choice of laboratory for each center will be made based on logistical proximity. Each NGS laboratory will have to determine and report clinical significance of alterations found using database search or other predictors to classify variants as deleterious or suspected deleterious. VUS have to be reported separately. Benign variants will be not reported in this study. All clinical and demographic data for patients with finished therapy will be collected in prospective or retrospective (where applicable) manner during the study visits. The second visit will take place when the disease progression or death is occurs or in a year after the first visit whichever happens first. Data will be entered in the eCRF. The site investigator will be responsible for ensuring that all required data is collected and entered into the eCRF with the involvement of clinical research organization. It is estimated that approximately 300 patients will be enrolled in the first stage. After interim analysis total number of the patients can be increased, depending on the number of NGS failures. It is estimated that approximately 30 sites in total will be participating in the study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Male 18 years age or older * Provision of written informed consent * Histologically confirmed diagnosis of prostate cancer * Documented evidence of metastatic castration resistant prostate cancer (mCRPC) * Patients who are on the first line therapy or already received one line of therapy due to mCRPC previously * Availability of archival FFPE tissue from primary prostate tumor * Availability of medical history (e.g. out-patient medical records or disease histories for hospitalized patients)

Exclusion criteria

• Patients participating in clinical studies

Design outcomes

Primary

Measure	Time frame
Differences in demographics between patients with HRRm and HRRwt mCRPC	Up to 1 year
Differences in treatment patterns between patients with HRRm and HRRwt mCRPC	Up to 1 year
Differences in clinical characteristics between patients with HRRm and HRRwt mCRPC	Up to 1 year
Progression-free survival (PFS) rate (time to documentation of objective tumor progression/relapse) stratified by tissue HRR-related gene mutation status and by treatment pattern	Up to 1 year

Countries

Russia

Outcome results